Brief: Ultimovacs ASA Provides Update On Phase 2 NIPU Trial Evaluating UV1 In Second-Line Patients With Malignant Pleural Mesothelioma

Zelluna ASA

07/06/2023 18:10

June 7 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * PROVIDES UPDATE ON PHASE II NIPU TRIAL EVALUATING UV1 IN
SECOND-LINE PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
    * CENTRAL INDEPENDENT REVIEW CONCLUDED THAT NIPU STUDY DID
NOT
MEET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS)
    * TWO ADDITIONAL ONGOING UV1 PHASE II TRIALS IN MALIGNANT
MELANOMA
AND HEAD AND NECK CANCER EXPECTED TO REPORT WITHIN A YEAR
    * ULTIMOVACS-TRIAL INVESTIGATORS ALSO OBSERVED IMPROVEMENT
IN
OVERALL SURVIVAL IN UV1 ARM OVER CONTROL ARM
    * SAFETY PROFILE WAS SIMILAR IN BOTH ARMS OF TRIAL,
CONFIRMING
GOOD SAFETY PROFILE FOR UV1

Source text for Eikon:  ID:nGNE8Zrbly 
Further company coverage:  ULTI.OL 

 ((Reuters.Briefs@thomsonreuters.com;;))